A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training
To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.
Wyeth is now a wholly owned subsidiary of Pfizer
United States: Food and Drug Administration
|Cleveland, Ohio 44195|
|Nashville, Tennessee 37203-1632|
|Louisville, Kentucky 40207|